Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Catalyst Pharma Expects FY22 Revenue Beat Consensus On Continued Recovery In Macroeconomic, Healthcare Activity

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) anticipates Q4 FY21 sales of approximately $38 million (consensus of $38.09 million), up roughly 24% Y/Y.

  • For FY21 total revenues are estimated to be approximately $141 million, an increase of roughly 18% Y/Y, better than the consensus of $138.3 million.
  • Last week, Catalyst announced that the District Court Judge in its case against the FDA had issued an order granting Catalyst Summary Judgment in its action against the FDA.
  • As a consequence of that order, the FDA has invalidated Jacobus Pharmaceutical Company Inc's Ruzurgi approval for pediatric patients with Lambert-Eaton myasthenic syndrome. 
  • The Company has ended the year with cash and investments of approximately $191 million, with no funded debt.
  • Guidance: The Company forecasts FY22 sales of $195 million - $205 million, representing a 38%-45% Y/Y increase, compared to the consensus of $163.53 million.
  • Price Action: CPRX shares are trading 6.04% at $5.97 during the market session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.